MCID: BLD062
MIFTS: 67

Bile Duct Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Bile Duct Cancer

MalaCards integrated aliases for Bile Duct Cancer:

Name: Bile Duct Cancer 12 20 54 42 15
Bile Duct Carcinoma 12 15 17
Extrahepatic Bile Duct Carcinoma 12 15
Extrahepatic Bile Duct Cancer 12 20
Malignant Neoplasm of the Extrahepatic Bile Duct 12
Carcinoma of Extrahepatic Bile Duct 12
Bile Duct Extrahepatic Carcinoma 54
Ca Extrahepatic Bile Ducts 12
Bile Duct Neoplasms 44
Bile Duct Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4606 DOID:4682 DOID:4897
ICD9CM 34 156.1
MeSH 44 D001650
ICD10 32 C24.0
UMLS 71 C0005396 C0153453 C0238019 more

Summaries for Bile Duct Cancer

GARD : 20 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 70567DefinitionCholangiocarcinoma (CCA) is a biliary tract cancer (BTC, see this term) originating in the epithelium of the biliary tree, either intra or extra hepatic.EpidemiologyThe prevalence is unknown but it accounts for approximately 3% of gastrointestinal tumors and 10-15% of all hepatobiliary malignancies.Clinical descriptionCCA can occur in the intra or extra-hepatic biliary tract. A specific type of extra-hepatic CCA known as a Klatskin tumor (see this term) occurs at the junction where the left and right hepatic bile ducts meet the common bile duct (CBD). It is slightly more prevalent in males than females (1.3:1.0) and usually presents in the fifth to seventh decade of life. Clinical manifestations are not usually noted until an advanced disease stage. Extra-hepatic CCA manifests with signs of cholestasis (jaundice, pale stools, dark urine, pruritus), malaise, weight loss and/or progressive weakness. Intra-hepatic CCA may present with an abdominal mass or with non-specific symptoms of decreased appetite, weight loss, abdominal pain and malaise.EtiologyThe etiology is unknown and most cases of CCA occur sporadically. Risk factors include primary sclerosing cholangitis (see this term), secondary sclerosing cholangitis, chronic typhoid carriage, parasitic infections (Opisthochis viverrini and Clonorchis sinensis), exposure to thorotrast (x-ray contrast medium) and choledochal cysts, all of which cause chronic biliary inflammation.Diagnostic methodsDiagnosis is suspected on clinical and laboratory findings. Serum carbohydrate antigen (CA) 19-9 is the glycoprotein tumor marker most often used in the diagnosis of CCA. It is found to be elevated in 85% of patients. Increased CEA levels are also noted. Extra-hepatic tumors cause increased levels of alkaline phosphate (ALP), conjugated bilirubin and gamma-glutamyl transpeptidase (GGT) while intra-hepatic have only slightly elevated ALP levels. Abdominal imaging, visualization of the biliary tree and biopsies of the lesion are necessary for diagnosis. Magnetic resonance cholangiopancreatography (MRCP) provides information on intrahepatic metastases, biliary anatomy and tumor extension and is used in the staging of CCA. It has been advocated to replace endoscopic retrograde cholangiopancreatography (ERCP), a more invasive method. Visualization of the biliary tree and samples through brush cytology or bile duct biopsies are obtained with ERCP. A needle biopsy is performed in those with a liver mass. Extra-hepatic CCA is further divided into anatomical subtypes according to the Bismuth classification and a disease stage is given. Ultrasound, and contrast enhanced helical computerized computed tomography (CT) can be used in visualizing the extent of disease.Differential diagnosisIntra-hepatic CCA is often mistaken for metastatic adenocarcinoma. Carcinoma of the gallbladder (see this term), benign strictures and Mirizzi syndrome should be excluded.Management and treatmentSurgical resection is the only potentially curative treatment for CCA but recurrences after surgery are frequent. Unfortunately CCA is often diagnosed as unresectable because of local extension and/or metastases. Distal CCA arising from the CBD is often treated by pancreatoduodenectomy. More proximal CCA needs hepatic resection. Palliative management involves biliary drainage by inserting metal stents in the biliary tree to release the blockage. Adjuvant chemotherapy after surgery or palliative chemotherapy for unresectable CCA is indicated. Gemcitabine combined with cisplatin therapy is the standard treatment for unresectable biliary tract cancers, including CCA.PrognosisAs proximal CCA is usually not diagnosed until a late stage of disease, prognosis is poor with 5-year survival rates of 20-50% after resection and almost 0% in unresectable tumors. Death is often due to biliary sepsis, cancer cachexia, malnutrition and liver failure.Visit the Orphanet disease page for more resources.

MalaCards based summary : Bile Duct Cancer, also known as bile duct carcinoma, is related to biliary tract cancer and cholangiocarcinoma. An important gene associated with Bile Duct Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Celecoxib and Antirheumatic Agents have been mentioned in the context of this disorder. Affiliated tissues include bile duct, liver and pancreas, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A biliary tract cancer that is located in the bile duct.

MedlinePlus : 42 Your liver makes a digestive juice called bile. Your gallbladder stores it between meals. When you eat, your gallbladder pushes the bile into tubes called bile ducts. They carry the bile to your small intestine. The bile helps break down fat. It also helps the liver get rid of toxins and wastes. Bile duct cancer is rare. It can happen in the parts of the bile ducts that are outside or inside the liver. Cancer of the bile duct outside of the liver is much more common. Risk factors include having inflammation of the bile duct, ulcerative colitis, and some liver diseases. Symptoms can include Jaundice Itchy skin Fever Abdominal pain Tests to diagnose bile duct cancer may include a physical exam, imaging tests of the liver and bile ducts, blood tests, and a biopsy. Treatments include surgery, radiation therapy, and chemotherapy. NIH: National Cancer Institute

Wikipedia : 74 Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts.... more...

Related Diseases for Bile Duct Cancer

Diseases in the Bile Duct Cancer family:

Bile Duct Carcinoma in Situ

Diseases related to Bile Duct Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 607)
# Related Disease Score Top Affiliating Genes
1 biliary tract cancer 32.7 SMAD4 MET EGFR
2 cholangiocarcinoma 32.5 VEGFA TP53 SMAD4 NCAM1 MET KRT7
3 intrahepatic cholangiocarcinoma 32.4 TP53 SMAD4 KRT7 KRT19 KRAS EGFR
4 bile duct cystadenocarcinoma 31.6 KRT7 CEACAM5 AFP
5 gallbladder cancer 31.5 TP53 KRAS EGFR CEACAM5 CDKN2A
6 in situ carcinoma 31.3 TP53 HRAS EGFR CDKN2A CCND1
7 tubular adenocarcinoma 31.3 KRT7 EGFR CEACAM5 AFP
8 cholangitis, primary sclerosing 31.2 KRT7 KRT19 IL6 CEACAM5 AFP
9 papillary adenocarcinoma 31.1 TP53 KRT7 KRT19 CEACAM5
10 cholecystitis 31.1 TP53 EGFR CDKN2A
11 bile duct cysts 31.0 KRT7 KRT19 KRAS HRAS CEACAM5 AFP
12 bile duct adenoma 30.8 TP53 NCAM1 KRT7 KRT19 CDKN2A
13 neuroendocrine carcinoma 30.8 NCAM1 KRT7 KRT19 CEACAM5
14 bile duct adenocarcinoma 30.8 TP53 MIR31 KRT7 KRT19 KRAS HRAS
15 pancreatic ductal adenocarcinoma 30.8 VEGFA TP53 SMAD4 MSLN MIR31 KRAS
16 small cell carcinoma 30.7 TP53 NCAM1 KRT7 KRT19 KRAS EGFR
17 adenoma 30.7 TP53 SMAD4 KRT7 KRAS CDKN2A CCND1
18 spindle cell sarcoma 30.7 VEGFA KRT7 IL6
19 cystadenoma 30.7 KRT7 CEACAM5 AFP
20 gastrointestinal carcinoma 30.7 TP53 KRT19 IL6 CEACAM5
21 adenosquamous carcinoma 30.7 TP53 SMAD4 KRT7 KRT19 KRAS EGFR
22 acinar cell carcinoma 30.6 TP53 SMAD4 KRT7 AFP
23 kidney cancer 30.6 VEGFA TP53 MET EGFR CDKN2A
24 fibrolamellar carcinoma 30.6 KRT7 KRT19 AFP
25 cystadenocarcinoma 30.6 VEGFA TP53 KRT7 HRAS CEACAM5
26 appendix adenocarcinoma 30.6 KRT7 KRAS HRAS CEACAM5
27 pancreatic acinar cell adenocarcinoma 30.6 KRT19 KRAS HRAS AFP
28 sarcoma 30.6 VEGFA TP53 KRAS IL6 HRAS CCND1
29 klatskin's tumor 30.6 TP53 KRT7 KRT19 CEACAM5 AFP
30 villous adenoma 30.5 TP53 KRT7 KRAS HRAS CEACAM5
31 neurofibromatosis, type i 30.5 TP53 NCAM1 KRAS HRAS EGFR CDKN2A
32 bladder cancer 30.5 VEGFA TP53 MIR31 KRT19 KRAS HRAS
33 pancreatic adenocarcinoma 30.5 VEGFA TP53 SMAD4 MET KRAS IL6
34 carcinosarcoma 30.5 TP53 KRT7 KRAS HRAS EGFR CDKN2A
35 ampulla of vater cancer 30.5 TP53 SMAD4 KRT7 KRAS HRAS CEACAM5
36 lynch syndrome 30.4 TP53 SMAD4 KRAS HRAS EGFR CDKN2A
37 papilloma 30.4 VEGFA TP53 KRT7 KRAS FSCN1 EGFR
38 adenocarcinoma 30.4 VEGFA TP53 SMAD4 MET KRT7 KRAS
39 mucinous adenocarcinoma 30.4 VEGFA TP53 KRT7 KRT19 KRAS EGFR
40 gastric adenocarcinoma 30.4 TP53 SMAD4 KRAS HRAS CEACAM5 CDKN2A
41 pancreatic cancer 30.3 VEGFA TP53 SMAD4 MSLN MIR31 MET
42 renal cell carcinoma, nonpapillary 30.3 VEGFA TP53 MSLN MIR31 MET KRT7
43 bile duct disease 30.3 TP53 KRT7 KRT19 KRAS IL6 HRAS
44 biliary tract disease 30.3 TP53 KRT7 KRT19 KRAS IL6 HRAS
45 esophageal cancer 30.3 VEGFA TP53 SMAD4 MIR31 KRT19 KRAS
46 leukemia, acute myeloid 30.2 VEGFA TP53 NCAM1 MIR31 KRAS IL6
47 hepatocellular carcinoma 30.0 VEGFA TP53 SMAD4 MIR31 MET KRT7
48 gastric cancer 30.0 VEGFA TP53 SMAD4 MET KRT19 KRAS
49 adenosquamous bile duct carcinoma 11.6
50 common bile duct neoplasm 11.4

Graphical network of the top 20 diseases related to Bile Duct Cancer:



Diseases related to Bile Duct Cancer

Symptoms & Phenotypes for Bile Duct Cancer

GenomeRNAi Phenotypes related to Bile Duct Cancer according to GeneCards Suite gene sharing:

26 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.91 EGFR HRAS KRAS NCAM1
2 Decreased viability GR00055-A-2 9.91 EGFR HRAS KRAS
3 Decreased viability GR00055-A-3 9.91 KRAS
4 Decreased viability GR00106-A-0 9.91 KRAS
5 Decreased viability GR00221-A-1 9.91 EGFR HRAS KRAS
6 Decreased viability GR00221-A-2 9.91 HRAS KRAS
7 Decreased viability GR00221-A-3 9.91 HRAS
8 Decreased viability GR00221-A-4 9.91 EGFR
9 Decreased viability GR00301-A 9.91 KRAS
10 Decreased viability GR00381-A-1 9.91 KRAS
11 Decreased cell migration GR00055-A-1 9.55 MET
12 Decreased cell migration GR00055-A-2 9.55 NCAM1
13 Decreased cell migration GR00055-A-3 9.55 EGFR HRAS NCAM1
14 Reduced mammosphere formation GR00396-S 9.23 AFP CCND1 EGFR HRAS KRAS KRT7

MGI Mouse Phenotypes related to Bile Duct Cancer:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.44 CCND1 CDKN2A CLDN18 EGFR FSCN1 IL6
2 endocrine/exocrine gland MP:0005379 10.37 AFP CCND1 CDKN2A CLDN18 EGFR HRAS
3 growth/size/body region MP:0005378 10.36 CCND1 CDKN2A CLDN18 EGFR FSCN1 HRAS
4 digestive/alimentary MP:0005381 10.35 CCND1 CDKN2A CLDN18 EGFR HRAS IL6
5 cardiovascular system MP:0005385 10.34 CCND1 CDKN2A EGFR HRAS IL6 KRAS
6 mortality/aging MP:0010768 10.32 AFP CCND1 CDKN2A EGFR FSCN1 HRAS
7 immune system MP:0005387 10.31 CCND1 CDKN2A CLDN18 EGFR FSCN1 IL6
8 integument MP:0010771 10.26 CCND1 CDKN2A EGFR FSCN1 HRAS IL6
9 nervous system MP:0003631 10.25 CCND1 CDKN2A CLDN18 EGFR FSCN1 HRAS
10 craniofacial MP:0005382 10.24 CCND1 EGFR HRAS KRAS KRT19 MET
11 embryo MP:0005380 10.22 CDKN2A EGFR FSCN1 KRAS KRT19 MET
12 neoplasm MP:0002006 10.21 AFP CCND1 CDKN2A EGFR HRAS IL6
13 liver/biliary system MP:0005370 10.19 AFP CDKN2A EGFR IL6 KRAS KRT19
14 muscle MP:0005369 10.11 CDKN2A EGFR HRAS IL6 KRAS MET
15 limbs/digits/tail MP:0005371 10.05 EGFR FSCN1 KRAS MET SMAD4 TP53
16 normal MP:0002873 10.02 CCND1 EGFR HRAS KRAS KRT19 MET
17 no phenotypic analysis MP:0003012 9.97 CDKN2A EGFR HRAS KRAS KRT19 MET
18 renal/urinary system MP:0005367 9.91 EGFR HRAS IL6 KRAS KRT7 MET
19 reproductive system MP:0005389 9.85 AFP CCND1 CDKN2A EGFR IL6 KRAS
20 respiratory system MP:0005388 9.73 CCND1 CDKN2A CLDN18 EGFR FSCN1 HRAS
21 skeleton MP:0005390 9.36 CCND1 CDKN2A CLDN18 EGFR HRAS IL6

Drugs & Therapeutics for Bile Duct Cancer

Drugs for Bile Duct Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 180)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
2 Antirheumatic Agents Phase 4
3 Analgesics, Non-Narcotic Phase 4
4 Cyclooxygenase 2 Inhibitors Phase 4
5 Anti-Inflammatory Agents, Non-Steroidal Phase 4
6 Cyclooxygenase Inhibitors Phase 4
7 Omega 3 Fatty Acid Phase 4
8 Ulipristal acetate Phase 4 126784-99-4
9
Arginine Investigational, Nutraceutical Phase 4 74-79-3 6322
10
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
11
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
12
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
13
Citalopram Approved Phase 3 59729-33-8 2771
14 Hematoporphyrin Derivative Phase 2, Phase 3
15 Folfirinox Phase 2, Phase 3
16 Albumin-Bound Paclitaxel Phase 3
17 Alkylating Agents Phase 2, Phase 3
18 Liver Extracts Phase 3
19 Cola Phase 3
20 Neurotransmitter Agents Phase 3
21 Antiparkinson Agents Phase 3
22 Cholinergic Antagonists Phase 3
23 Psychotropic Drugs Phase 3
24 Antidepressive Agents Phase 3
25 Muscarinic Antagonists Phase 3
26 Serotonin Uptake Inhibitors Phase 3
27 Parasympatholytics Phase 3
28 Cholinergic Agents Phase 3
29
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
30
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
31
Pemetrexed Approved, Investigational Phase 1, Phase 2 150399-23-8, 137281-23-3 446556 60843
32
Hydroxyurea Approved Phase 2 127-07-1 3657
33
Lenograstim Approved, Investigational Phase 2 135968-09-1
34
Fosaprepitant Approved Phase 2 172673-20-0 219090
35
Aprepitant Approved, Investigational Phase 2 170729-80-3 151165 6918365
36
Epirubicin Approved Phase 1, Phase 2 56420-45-2 41867
37
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
38
Bevacizumab Approved, Investigational Phase 2 216974-75-3
39
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
40
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
41
Temoporfin Approved, Investigational Phase 2 122341-38-2
42
Trifluridine Approved, Investigational Phase 2 70-00-8 6256
43
Durvalumab Approved, Investigational Phase 2 1428935-60-7
44
Olaparib Approved Phase 2 763113-22-0 23725625
45
Vinblastine Approved Phase 1, Phase 2 865-21-4 13342 241903
46
Coal tar Approved Phase 1, Phase 2 8007-45-2
47
Ipilimumab Approved Phase 1, Phase 2 477202-00-9
48
Pembrolizumab Approved Phase 2 1374853-91-4
49
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
50
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838

Interventional clinical trials:

(show top 50) (show all 173)
# Name Status NCT ID Phase Drugs
1 Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer. Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
2 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Hepatectomy Completed NCT01256047 Phase 4
3 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
4 Covered Versus Uncovered Metal Stents for Management of Distal Malignant Biliary Obstruction? Results of a Randomized Prospective Study. Completed NCT00280709 Phase 4
5 Prospective Randomized Trial Comparing Covered Metal Stents Placed Above and Across the Sphincter of Oddi in Malignant Biliary Obstruction: A Multi-nation, Multi-center Study Completed NCT01041612 Phase 4
6 The Effect of Individualized Precision Therapy Programs in Patients With Biliary Tract Cancer Recruiting NCT02943031 Phase 4
7 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Unknown status NCT02798510 Phase 3 capecitabine;gemcitabine
8 Open-label Observational Study of Plastic Cylindrical Fiber Optic Diffuser (Pioneer Optics) in Photodynamic Therapy for the Management of Cholangiocarcinoma. Unknown status NCT01755013 Phase 2, Phase 3
9 A Prospective, Randomized Trial of Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
10 Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
11 Gemcitabine, Alone or in Combination With Cisplatin, in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumors: A Multicentre, Randomized Phase III Study Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
12 Randomized Phase II-III Study of Chemoradiation With Fluorouracil and Cisplatin Versus Chemotherapy (Gemcitabine/Oxaliplatin) in Non Resectable But Non Metastatic Cancer of the Biliary Tract Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
13 A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
14 Porfimer Sodium Photodynamic Therapy Plus Stenting Versus Stenting Alone in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumours: a Multicentre, Randomised, Phase Lll Study Completed NCT00513539 Phase 3 porfimer sodium
15 Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours Completed NCT02591030 Phase 2, Phase 3 GEMCIS;mFolfirinox
16 Phase III Randomized Controlled Trial of a Collaborative Care Intervention to Manage Cancer Related Symptoms in Patients Diagnosed With Hepatobiliary Carcinoma Completed NCT01640522 Phase 3
17 Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies Completed NCT02349412 Phase 3
18 A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers Recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
19 Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine Versus Cisplatin/Gemcitabine in Patients With IntraHepatic Cholangiocarcinoma Recruiting NCT03086993 Phase 2, Phase 3 Cisplatin and Gemcitabine
20 Impact of Early Palliative Care on Overall Survival of Patients With Metastatic Upper Gastrointestinal Cancers, Treated With First-line Chemotherapy: a Randomized Phase III Trial Recruiting NCT02853474 Phase 3
21 A Phase III Study of Gemcitabine Plus Capecitabine (GEMCAP) Versus Gemcitabine Alone in Advanced Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
22 Symptom Management Trial in Cancer Survivors Terminated NCT00387348 Phase 3 escitalopram oxalate;Placebo
23 Comparison Between Two Methods of Bilateral Stenting for Malignant Hilar Obstruction Withdrawn NCT01622803 Phase 3
24 Phase III Randomized Study of Double Plastic Endoprosthesis Insertion With Versus Without Adjuvant Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Patients With Unresectable Stage III-IV Cholangiocarcinoma Withdrawn NCT00253617 Phase 3 porfimer sodium
25 Open One-Arm Therapy Optimizing Trial on Regional Chemotherapy of the Liver Through an Interventionally Implanted A.Hepatica Port System in Patients With Liver Metastases or Primary Liver Neoplasms. Unknown status NCT00356161 Phase 2
26 Study Of Gemcitabine, Leukovorin, And Fluorouracil Used To Treat Locally Advanced And Metastatic Pancreatic And Biliary Adenocarcinomas Unknown status NCT00010088 Phase 2 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
27 Phase II Study of TLC D-99 for Hepatobiliary Carcinomas Unknown status NCT00003296 Phase 2 pegylated liposomal doxorubicin hydrochloride
28 A Phase II, Open-label, Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma Unknown status NCT01016002 Phase 2 Temoporfin
29 A Randomized, Open, Prospective Clinical Research Programs of Fluorouracil Implant (Sinofuan) to Improve Surgical Gallbladder Cancer and Bile Duct Cancer Unknown status NCT01317069 Phase 2 Fluorouracil implant
30 Phase II Study to Evaluate the Efficacy of a Chemotherapy Combination With Imatinib (Glivec®) and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile Duct Completed NCT01153750 Phase 2 Glivec
31 Phase II Trial Of Gemcitabine, 5-Fluorouracil, And Leucovorin In Patients With Measurable Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Of Vater) And Gallbladder Carcinoma Completed NCT00009893 Phase 2 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
32 A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Biliary Tree Cancer (Cholangiocarcinoma and Gallbladder Cancer) Completed NCT00005938 Phase 2 exatecan mesylate
33 A Phase II Trial of Dolastatin-10 (NSC 376128) Administered as an IV Bolus Every 3 Weeks in Patients With Hepatobiliary Cancer Completed NCT00003557 Phase 2 dolastatin 10
34 Phase I/II Trial Of Gemcitabine And ALIMTA In Patients With Measurable Or Evaluable, Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Or Vater) And Gallbladder Carcinoma Completed NCT00059865 Phase 1, Phase 2 gemcitabine hydrochloride;pemetrexed disodium
35 A Phase II Study of Gemcitabine in Combination With Capecitabine in Advanced Cholangiocarcinoma Completed NCT00084942 Phase 2 capecitabine;gemcitabine hydrochloride
36 Capecitabine And Gemcitabine In Patients With Advanced Or Metastatic Biliary Tract Cancer, A Multicenter Phase II Trial Completed NCT00073905 Phase 2 capecitabine plus gemcitabine
37 A Phase II Trial of Gemcitabine (NSC-613327) and Capecitabine (NSC-712807) in Patients With Unresectable or Metastatic Gallbladder or Cholangiocarcinoma Completed NCT00033540 Phase 2 capecitabine;gemcitabine hydrochloride
38 Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
39 Phase II Study of Photodynamic Therapy With PHOTOFRIN (Porfimer Sodium) for Injection in Patients With Malignant Bile Duct Obstruction Completed NCT00003923 Phase 2 porfimer sodium
40 A Feasibility Study to Discern the Tolerability of 5-FU/Gemcitabine Based Chemotherapy Concurrent With Upper Abdominal Radiation and the Utility of Aprepitant/5HT-3 Antagonist (EMEND) for the Prevention of ChemoRadiation-Induced Nausea and Vomiting (CRINV) Completed NCT01534637 Phase 2 aprepitant;gemcitabine hydrochloride;capecitabine;fluorouracil
41 A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC) Completed NCT00789958 Phase 2 capecitabine;gemcitabine hydrochloride
42 A Phase II Study of Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naïve to Systemic Therapy Completed NCT00919061 Phase 2 Gemcitabine;Cisplatin;Sorafenib
43 A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy Completed NCT01954745 Phase 2 Cabozantinib
44 A Pilot Open-Label Clinical Trial of CPI-613 in Patients With Advanced Bile Duct Cancers Completed NCT01766219 Phase 1, Phase 2 6,8-bis(benzylthio)octanoic acid
45 An Open-label, Uncontrolled, Phase II Trial Evaluating the Single-dose and Steady-state Pharmacokinetics of EndoTAG®-1 and Its Effect on the Blood Supply and the Angiogenesis of Hepatic Metastases in Patients With a Carcinomatous Primary Tumor Other Than Hepatocellular (HCC), Biliary or Bile Duct Carcinoma Completed NCT00542048 Phase 2 EndoTAG®-1
46 A Phase II Study of CPT-11 in Patients With Advanced Gallbladder or Bile Duct Tumors Completed NCT00003276 Phase 2 irinotecan hydrochloride
47 Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients With Advanced Gallbladder Carcinoma or Cholangiocarcinoma Completed NCT01093222 Phase 2 Erlotinib Hydrochloride;Sorafenib Tosylate
48 A Phase II Study of GW572016 (Lapatanib) in Locally Advanced or Metastatic Hepato-Biliary Cancers Completed NCT00101036 Phase 2 lapatinib ditosylate
49 A Phase I/II Trial of Epirubicin, Carboplatin & Capecitabine in Adult Cancer Patients Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
50 A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy Completed NCT00004910 Phase 1, Phase 2

Search NIH Clinical Center for Bile Duct Cancer

Cochrane evidence based reviews: bile duct neoplasms

Genetic Tests for Bile Duct Cancer

Anatomical Context for Bile Duct Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Bile Duct Cancer:

19
Bile Duct

MalaCards organs/tissues related to Bile Duct Cancer:

40
Liver, Pancreas, Small Intestine, Lymph Node, Colon, Endothelial, T Cells

Publications for Bile Duct Cancer

Articles related to Bile Duct Cancer:

(show top 50) (show all 2081)
# Title Authors PMID Year
1
Diagnosis of intrahepatic cholangiocarcinoma by Raman spectroscopy provides high efficiency: A protocol for systematic review and meta-analysis. 42
33429751 2021
2
Extended lymph node resection versus standard resection for pancreatic and periampullary adenocarcinoma. 42
33471373 2021
3
Effects of microvascular invasion on clinical outcomes after resection with curative intent for cholangiocarcinoma. 42
33350747 2020
4
Significance of mucin expression in pancreatobiliary neoplasms. 54 61
19787286 2010
5
Four primary malignancies successively occurred in a BRCA2 mutation carrier: a case report. 54 61
16982466 2006
6
CDX2 and MUC2 protein expression in extrahepatic bile duct carcinoma. 54 61
16191504 2005
7
Immunohistochemical expression of matrix metalloproteinases in bile duct cancer tissue. 61 54
15682828 2004
8
Down-regulated p16 expression predicts poor prognosis in patients with extrahepatic biliary tract carcinomas. 54 61
11836554 2002
9
Genetic detection for micrometastasis in lymph node of biliary tract carcinoma. 54 61
10873083 2000
10
Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. 61 54
8611434 1996
11
Neural cell adhesion molecule and perineural invasion in gallbladder cancer. 54 61
7844990 1995
12
Neural cell adhesion molecule (NCAM) and perineural invasion in bile duct cancer. 54 61
8501910 1993
13
[Role of carcinoembryonic antigen, carbohydrate antigen 19-9 and cytology of bile in diagnosis of biliary and pancreatic cancer]. 54 61
1886576 1991
14
Cholangiocarcinoma miscoding in hepatobiliary centres. 61
33032867 2021
15
Liver Transplantation for Perihilar Cholangiocarcinoma: patient selection and outcomes. 61
33577361 2021
16
Association between gallstones and the risk of biliary tract cancer: a systematic review and meta-analysis. 61
33541011 2021
17
Adenomyomatous hyperplasia of the extrahepatic bile duct: a systematic review of a rare lesion mimicking bile duct carcinoma. 61
33400191 2021
18
Central hepatopancreatoduodenectomy-oncological effectiveness and parenchymal sparing option for diffusely spreading bile duct cancer: report of two cases. 61
33407366 2021
19
Radiologic Evaluation and Structured Reporting Form for Extrahepatic Bile Duct Cancer: 2019 Consensus Recommendations from the Korean Society of Abdominal Radiology. 61
32901457 2021
20
Bile Metabolites and Risk of Carcinogenesis in Patients With Pancreaticobiliary Maljunction: A Pilot Study. 61
33419827 2021
21
Reversine, a selective MPS1 inhibitor, induced autophagic cell death via diminished glucose uptake and ATP production in cholangiocarcinoma cells. 61
33505802 2021
22
The clinical significance of preoperative C-reactive protein/albumin ratio in patients with resected extrahepatic bile duct cancer. 61
33387024 2021
23
[A case of distal bile duct carcinoma converted to neuroendocrine cancer and proliferated into the pancreas]. 61
33563857 2021
24
Investigation of possible alternate animal reservoir hosts of Opisthorchis viverrini. 61
33524385 2021
25
Diagnostic accuracy of administrative database for bile duct cancer by ICD-10 code in a tertiary institute in Korea. 61
32249128 2020
26
A case of stent-graft implantation for postpancreaticoduodenectomy hemorrhage in a patient with a reconstructed gastric tube. 61
33117472 2020
27
Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials. 61
33037430 2020
28
Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells. 61
33242709 2020
29
Monitoring the Progression of Liver Fluke-Induced Cholangiocarcinoma in a Hamster Model Using Synchrotron FTIR Microspectroscopy and Focal Plane Array Infrared Imaging. 61
33170647 2020
30
Gramicidin inhibits cholangiocarcinoma cell growth by suppressing EGR4. 61
31852273 2020
31
IgG4-related autoimmune liver disease. 61
33267565 2020
32
Hepatitis B virus infection and the risk of cancer among the Chinese population. 61
32478856 2020
33
Therapeutic results of Denver percutaneous peritoneovenous shunt in cancer patients with malignant ascites. 61
33380660 2020
34
Direct visualization of an intraductal papillary neoplasm of the bile duct: A premalignant lesion of bile duct cancer. 61
33262052 2020
35
Clinical Utility of Bile Duct Axis Deviation for Differential Diagnosis Between Pancreatic Head Cancer and Bile Duct Cancer. 61
33153309 2020
36
[18F]-FDG PET/CT in a case of metastatic extrahepatic bile duct cancer from sigmoid carcinoma. 61
33200299 2020
37
Liquid biopsy and multi-analyte testing guided treatment of HER2 positive periampullary adenocarcinoma with durable complete response after trastuzumab based therapy. 61
33227091 2020
38
Low H3K9me3 Expression Is Associated With Poor Prognosis in Patients With Distal Common Bile Duct Cancer. 61
33144476 2020
39
Histological evaluation of tumor differentiation score and prognosis of extrahepatic bile duct cancer: A proposal for a new histological grading system. 61
32909295 2020
40
Cholangioscopy- versus fluoroscopy-guided transpapillary mapping biopsy for preoperative evaluation of extrahepatic cholangiocarcinoma: a prospective randomized crossover study. 61
33141278 2020
41
Foodborne zoonotic parasites of the family Opisthorchiidae. 61
33158552 2020
42
Criteria for liver resection for metastasis from bile duct cancer. 61
33034741 2020
43
A multicenter prospective randomized controlled trial for preoperative biliary drainage with uncovered metal versus plastic stents for resectable periampullary cancer. 61
32713115 2020
44
Characterization and in vitro functional analysis of thioredoxin glutathione reductase from the liver fluke Opisthorchis viverrini. 61
32659283 2020
45
Associations between reproductive factors and biliary tract cancers in women from the Biliary Tract Cancers Pooling Project. 61
32437829 2020
46
[Diagnosis and treatment of gastric cancer with immediate double primary carcinoma]. 61
33086451 2020
47
Duplication of extrahepatic bile duct with lower common bile duct cancer. 61
32506825 2020
48
Prognostic effects of histology-based tumour microenvironment scores in resected distal bile duct cancer. 61
32473032 2020
49
Hepatopancreatoduodenectomy -a controversial treatment for bile duct and gallbladder cancer from a European perspective. 61
31899044 2020
50
Synchronous Double Bile Duct Cancers with Distinct Genetic Features. 61
32493852 2020

Variations for Bile Duct Cancer

Cosmic variations for Bile Duct Cancer:

9 (show top 50) (show all 9120)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM140721366 ZNF521 biliary tract,gallbladder,carcinoma,adenocarcinoma c.835T>C p.S279P 18:25226423-25226423 12
2 COSM94799464 ZNF521 biliary tract,gallbladder,carcinoma,adenocarcinoma c.1495T>C p.S499P 18:25226423-25226423 12
3 COSM94795627 ZNF521 biliary tract,gallbladder,carcinoma,adenocarcinoma c.-1-75G>A p.? 18:25351022-25351022 12
4 COSM131506278 ZNF521 biliary tract,gallbladder,carcinoma,adenocarcinoma c.1495T>C p.S499P 18:25226423-25226423 12
5 COSM131502102 ZNF521 biliary tract,gallbladder,carcinoma,adenocarcinoma c.-47-29G>A p.? 18:25351022-25351022 12
6 COSM140717571 ZNF521 biliary tract,gallbladder,carcinoma,adenocarcinoma c.-621+983G>A p.? 18:25351022-25351022 12
7 COSM125149394 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.4538G>A p.R1513H 8:76851537-76851537 12
8 COSM127376784 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.4616G>A p.R1539H 8:76851537-76851537 12
9 COSM127371571 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.10571A>C p.K3524T 8:76864285-76864285 12
10 COSM125144409 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.10493A>C p.K3498T 8:76864285-76864285 12
11 COSM125186347 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.1738G>T p.G580* 8:76705826-76705826 12
12 COSM127365243 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.*1399G>A p.? 8:76865964-76865964 12
13 COSM125180058 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.*345G>T p.? 8:76864910-76864910 12
14 COSM127406292 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.*345G>T p.? 8:76864910-76864910 12
15 COSM127412310 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.1738G>T p.G580* 8:76705826-76705826 12
16 COSM127412300 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.-71G>A p.? 8:76681596-76681596 12
17 COSM149327014 ZFHX3 biliary tract,gallbladder,carcinoma,adenocarcinoma c.3003G>A p.L1001= 16:72950682-72950682 12
18 COSM87276533 ZFHX3 biliary tract,bile duct,carcinoma,adenocarcinoma c.6964C>T p.R2322* 16:72795718-72795718 12
19 COSM87294455 ZFHX3 biliary tract,gallbladder,carcinoma,adenocarcinoma c.3003G>A p.L1001= 16:72950682-72950682 12
20 COSM87284738 ZFHX3 biliary tract,gallbladder,carcinoma,adenocarcinoma c.*2655C>T p.? 16:72784509-72784509 12
21 COSM102048118 ZFHX3 biliary tract,bile duct,carcinoma,adenocarcinoma c.787+1G>A p.? 16:72829778-72829778 12
22 COSM102045430 ZFHX3 biliary tract,gallbladder,carcinoma,adenocarcinoma c.261G>A p.L87= 16:72950682-72950682 12
23 COSM149332377 ZFHX3 biliary tract,bile duct,carcinoma,adenocarcinoma c.3529+1G>A p.? 16:72829778-72829778 12
24 COSM87296816 ZFHX3 biliary tract,bile duct,carcinoma,adenocarcinoma c.3529+1G>A p.? 16:72829778-72829778 12
25 COSM102025189 ZFHX3 biliary tract,bile duct,carcinoma,adenocarcinoma c.4222C>T p.R1408* 16:72795718-72795718 12
26 COSM149275977 ZFHX3 biliary tract,bile duct,carcinoma,adenocarcinoma c.6964C>T p.R2322* 16:72795718-72795718 12
27 COSM149299892 ZFHX3 biliary tract,gallbladder,carcinoma,adenocarcinoma c.*2655C>T p.? 16:72784509-72784509 12
28 COSM102035174 ZFHX3 biliary tract,gallbladder,carcinoma,adenocarcinoma c.*2655C>T p.? 16:72784509-72784509 12
29 COSM90947216 YAP1 biliary tract,bile duct,carcinoma,adenocarcinoma c.434C>G p.T145S 11:102114256-102114256 12
30 COSM127997056 YAP1 biliary tract,bile duct,carcinoma,adenocarcinoma c.434C>G p.T145S 11:102114256-102114256 12
31 COSM145027300 YAP1 biliary tract,bile duct,carcinoma,adenocarcinoma c.434C>G p.T145S 11:102114256-102114256 12
32 COSM128451074 YAP1 biliary tract,bile duct,carcinoma,adenocarcinoma c.434C>G p.T145S 11:102114256-102114256 12
33 COSM126972057 YAP1 biliary tract,bile duct,carcinoma,adenocarcinoma c.-101C>G p.? 11:102114256-102114256 12
34 COSM85236535 YAP1 biliary tract,bile duct,carcinoma,adenocarcinoma c.434C>G p.T145S 11:102114256-102114256 12
35 COSM143040603 YAP1 biliary tract,bile duct,carcinoma,adenocarcinoma c.434C>G p.T145S 11:102114256-102114256 12
36 COSM133273136 YAP1 biliary tract,bile duct,carcinoma,adenocarcinoma c.434C>G p.T145S 11:102114256-102114256 12
37 COSM104236735 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.729G>T p.E243D 2:61498703-61498703 12
38 COSM104240798 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.273G>T p.W91C 2:61522639-61522639 12
39 COSM101978949 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.338C>T p.T113M 2:61502274-61502274 12
40 COSM101977429 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.729G>T p.E243D 2:61498703-61498703 12
41 COSM104888049 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.273G>T p.W91C 2:61522639-61522639 12
42 COSM104238660 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.338C>T p.T113M 2:61502274-61502274 12
43 COSM104883338 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.729G>T p.E243D 2:61498703-61498703 12
44 COSM101981179 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.273G>T p.W91C 2:61522639-61522639 12
45 COSM104885218 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.338C>T p.T113M 2:61502274-61502274 12
46 COSM91375813 WT1 biliary tract,gallbladder,carcinoma,adenocarcinoma c.1229T>C p.M410T 11:32396277-32396277 12
47 COSM111531901 WT1 biliary tract,gallbladder,carcinoma,adenocarcinoma c.1178T>C p.M393T 11:32396277-32396277 12
48 COSM113478099 WT1 biliary tract,gallbladder,carcinoma,adenocarcinoma c.1229T>C p.M410T 11:32396277-32396277 12
49 COSM147427179 WT1 biliary tract,gallbladder,carcinoma,adenocarcinoma c.441C>T p.G147= 11:32434905-32434905 12
50 COSM149740900 WT1 biliary tract,gallbladder,carcinoma,adenocarcinoma c.441C>T p.G147= 11:32434905-32434905 12

Expression for Bile Duct Cancer

Search GEO for disease gene expression data for Bile Duct Cancer.

Pathways for Bile Duct Cancer

Pathways related to Bile Duct Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 VEGFA TP53 SMAD4 MET KRAS IL6
2
Show member pathways
13.74 VEGFA TP53 SMAD4 MET KRAS IL6
3
Show member pathways
13.59 VEGFA TP53 SMAD4 MET KRAS IL6
4
Show member pathways
13.56 VEGFA SMAD4 NCAM1 MET KRT7 KRT19
5
Show member pathways
13.41 VEGFA TP53 NCAM1 MET KRAS IL6
6
Show member pathways
13.13 TP53 SMAD4 KRAS IL6 HRAS EGFR
7
Show member pathways
13.11 TP53 MET KRAS IL6 HRAS EGFR
8
Show member pathways
13.06 VEGFA TP53 MET KRAS IL6 HRAS
9
Show member pathways
13.01 VEGFA TP53 KRAS IL6 HRAS EGFR
10
Show member pathways
12.96 VEGFA MET KRAS HRAS EGFR CCND1
11
Show member pathways
12.94 VEGFA TP53 SMAD4 KRAS HRAS EGFR
12
Show member pathways
12.83 TP53 SMAD4 MET KRAS HRAS EGFR
13 12.82 VEGFA TP53 MET KRAS HRAS EGFR
14
Show member pathways
12.78 VEGFA MET KRAS HRAS EGFR
15
Show member pathways
12.77 TP53 MET KRAS HRAS EGFR
16
Show member pathways
12.76 TP53 MET KRAS HRAS EGFR CDKN2A
17
Show member pathways
12.72 SMAD4 KRAS HRAS EGFR CCND1
18
Show member pathways
12.72 VEGFA KRT19 KRAS HRAS EGFR
19
Show member pathways
12.65 TP53 KRAS IL6 HRAS EGFR
20
Show member pathways
12.59 VEGFA TP53 SMAD4 KRAS HRAS EGFR
21
Show member pathways
12.59 VEGFA TP53 MET KRAS IL6 HRAS
22 12.58 VEGFA TP53 SMAD4 MET KRAS IL6
23
Show member pathways
12.56 TP53 MET KRAS HRAS EGFR
24
Show member pathways
12.5 TP53 MET KRAS HRAS EGFR
25
Show member pathways
12.44 MET KRAS IL6 HRAS EGFR
26
Show member pathways
12.43 TP53 MET HRAS CCND1
27 12.41 TP53 SMAD4 CDKN2A CCND1
28
Show member pathways
12.38 TP53 IL6 HRAS EGFR CCND1
29
Show member pathways
12.38 VEGFA TP53 KRAS HRAS EGFR
30 12.37 TP53 KRAS HRAS CDKN2A CCND1
31 12.34 TP53 SMAD4 KRAS IL6 HRAS CDKN2A
32
Show member pathways
12.33 TP53 MET KRAS IL6 EGFR
33
Show member pathways
12.32 TP53 MET KRAS HRAS EGFR CCND1
34 12.26 VEGFA TP53 MET KRAS HRAS EGFR
35 12.25 TP53 KRAS IL6 HRAS CDKN2A CCND1
36 12.23 VEGFA TP53 SMAD4 KRAS EGFR CCND1
37
Show member pathways
12.16 SMAD4 KRAS IL6 HRAS EGFR CCND1
38 12.15 SMAD4 KRAS HRAS CCND1
39 12.14 VEGFA NCAM1 MET KRT19 IL6 AFP
40
Show member pathways
12.13 TP53 KRAS HRAS EGFR
41 12.13 TP53 SMAD4 MET CCND1
42 12.12 TP53 MET EGFR AFP
43
Show member pathways
12.11 KRAS HRAS EGFR CCND1
44 12.08 TP53 KRAS HRAS CCND1
45 12.08 VEGFA TP53 IL6 FSCN1 CCND1
46 12.07 TP53 IL6 EGFR CCND1
47 12.04 TP53 SMAD4 IL6 HRAS CDKN2A
48 12.03 TP53 SMAD4 KRAS HRAS CDKN2A CCND1
49 12.02 VEGFA TP53 SMAD4 KRAS IL6 EGFR
50 12 TP53 KRAS HRAS EGFR CDKN2A CCND1

GO Terms for Bile Duct Cancer

Cellular components related to Bile Duct Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 anchored component of membrane GO:0031225 9.26 NCAM1 MSLN CEACAM5 CD24
2 cell surface GO:0009986 9.17 VEGFA NCAM1 MSLN MET EGFR CEACAM5

Biological processes related to Bile Duct Cancer according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.01 VEGFA TP53 SMAD4 MET IL6 HRAS
2 positive regulation of cell proliferation GO:0008284 10 VEGFA KRAS IL6 HRAS EGFR CCND1
3 negative regulation of cell proliferation GO:0008285 9.99 TP53 SMAD4 IL6 HRAS CDKN2A
4 positive regulation of gene expression GO:0010628 9.91 VEGFA TP53 KRAS IL6 HRAS CDKN2A
5 MAPK cascade GO:0000165 9.88 NCAM1 MET KRAS HRAS EGFR
6 positive regulation of protein phosphorylation GO:0001934 9.77 VEGFA KRAS HRAS EGFR CCND1
7 response to glucocorticoid GO:0051384 9.76 KRAS IL6 CCND1
8 positive regulation of epithelial cell proliferation GO:0050679 9.73 VEGFA HRAS EGFR
9 response to estrogen GO:0043627 9.72 KRT19 CD24 CCND1
10 liver regeneration GO:0097421 9.67 IL6 EGFR CCND1
11 intrinsic apoptotic signaling pathway GO:0097193 9.63 TP53 HRAS CD24
12 cytokine-mediated signaling pathway GO:0019221 9.63 VEGFA TP53 KRAS IL6 FSCN1 CCND1
13 Ras protein signal transduction GO:0007265 9.62 TP53 KRAS HRAS CDKN2A
14 mitotic G1 DNA damage checkpoint GO:0031571 9.6 TP53 CCND1
15 positive regulation of extracellular matrix disassembly GO:0090091 9.58 IL6 FSCN1
16 response to isolation stress GO:0035900 9.57 KRAS HRAS
17 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.54 VEGFA TP53
18 response to UV-A GO:0070141 9.51 EGFR CCND1
19 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.43 TP53 IL6 EGFR
20 liver development GO:0001889 9.35 MET KRAS HRAS EGFR CCND1
21 positive regulation of MAP kinase activity GO:0043406 9.02 VEGFA KRAS HRAS EGFR CD24

Molecular functions related to Bile Duct Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.96 VEGFA TP53 SMAD4 NCAM1 MSLN MIR31
2 protein kinase binding GO:0019901 9.72 TP53 EGFR CDKN2A CD24 CCND1
3 protein-containing complex binding GO:0044877 9.55 KRT19 KRAS HRAS EGFR CCND1
4 identical protein binding GO:0042802 9.28 VEGFA TP53 SMAD4 NCAM1 MET KRAS
5 MDM2/MDM4 family protein binding GO:0097371 9.26 TP53 CDKN2A

Sources for Bile Duct Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....